-
调节性T细胞(Treg)是抑制机体免疫应答, 诱导机体免疫耐受的一种T细胞亚群。乙型肝炎(乙肝)病毒(HBV)的清除依赖于T细胞,CD8+T细胞是从肝脏中清除HBV的关键细胞。Treg在外围以及肿瘤区域表达较多的Foxp3和特异性抑制CD8+T细胞的活性,从而阻断病毒的特异性免疫反应,导致病毒的持久性[1-3]。目前核苷(酸)类似物是慢性乙肝病人的主要治疗手段,但该类药物治疗期间Treg水平变化与病情不同转归之间的关系尚无定论。本实验通过分析慢性乙肝病人不同感染状态下CD4+CD25+Treg细胞表达水平的差异以及接受核苷(酸)类似物治疗48周后ALT、HBV是否复常,乙肝e抗原(HBeAg)不同血清学变化等情况与CD4+CD25+Treg之间的关系,对核苷类似物治疗预后及预测进行了相关探讨。现作报道。
核苷(酸)类似物对慢性乙型肝炎的疗效及与外周血调节性T细胞的相关性
Effect of the nucleoside analogues in the treatment of chronic hepatitis B and its correlation with regulatory T cells of peripheral blood
-
摘要:
目的探讨核苷(酸)类似物治疗过程中慢性乙型肝炎(CHB)病人外周血中调节性T细胞(Treg)表达水平的变化及临床意义。 方法选取130例接受核苷(酸)类似物治疗的CHB病人,治疗前及治疗48周时,分别以流式细胞仪检测外周血CD4+CD25+CD127Low/- Tregs比例。 结果治疗前,免疫耐受组、免疫清除组及健康对照组间CD4+CD25+CD127Low/- Treg水平差异有统计学意义(P < 0.01),其中免疫清除组与免疫耐受组和健康对照组差异均有统计学意义(P < 0.01和P < 0.05),而免疫清除组与健康对照组差异无统计学意义(P>0.05);治疗48周时,HBeAg未变化组、HBeAg转阴组、HBeAg血清转换组、健康对照组CD4+CD25+CD127Low/- Treg细胞水平差异均有统计学意义(P < 0.05),HBeAg未变化组与HBeAg转阴组和健康对照组Treg细胞差异均有统计学意义(P < 0.05),而HBeAg转阴组、HBeAg血清转换组与健康对照组差异无统计学意义(P>0.05);48周治疗后乙型肝炎病毒(HBV)复常组与HBV未复常组Treg差异无统计学意义(P>0.05);ALT复常组与ALT未复常组差异无统计学意义(P>0.05)。 结论CHB病人经核苷(酸)类似物治疗过程中CD4+CD25+CD127Low/- Treg细胞水平变化与HBeAg是否发生血清转换、HBV是否复常有关,对核苷(酸)类似物治疗的疗效及预后有一定的预测价值。 -
关键词:
- 乙型肝炎 /
- T淋巴细胞, 调节性 /
- 核苷类似物 /
- 抗病毒治疗
Abstract:ObjectiveTo investigate the expression levels of regulatory T cells (Treg) in peripheral blood of chronic hepatitis B (CHB) patients during the treatment with nucleoside analogues, and its clinical significance. MethodsThe ratio of CD4+CD25+CD127Low/- Tregs in 130 CHB patients treated with nucleoside analogues was detected using flow cytometry before treatment and after 48 weeks of treatment. ResultsBefore treatment, the differences of the levels of CD4+CD25+CD127Low/- Treg among immune tolerance group, immune clearance group and healthy control group were statistically significant (P < 0.01), the differences of the levels of CD4+CD25+CD127Low/- Treg between immune tolerance group, and immune clearance group, healthy control group were statistically significant (P < 0.01 and P < 0.05), but the difference of the level CD4+CD25+CD127Low/- Treg between immune clearance group and healthy control group was not statistically significant (P>0.05).After 48 weeks of treatment, the differences of the levels of CD4+CD25+CD127Low/- Treg among HBeAg unchanged group, HBeAg conversion negative group, HBeAg serum conversion group and healthy control group were statistically significant (P < 0.05), the differences of the levels of CD4+CD25+CD127Low/- Treg between HBeAg unchanged group and HBeAg conversion negative group, healthy control group were statistically significant (P < 0.05), and the differences of the levels of CD4+CD25+CD127Low/- Treg among HBeAg conversion negative group, HBeAg serum conversion group and healthy control group were not statistically significant (P>0.05).After 48 weeks of treatment, the difference of the level of Treg between HBV normalization group and HBV no normalization group was not statistically significant (P>0.05), and the difference of the level of Treg between ALT normalization group and ALT no normalization group was not statistically significant (P>0.05). ConclusionsDuring the treatment of CHB patients with nucleoside analogues, the level of CD4+CD25+CD127Low/- Treg may be related to the HBeAg seroconversion and HBV normalization, which has certain predictive value in the efficacy and prognosis of disease. -
Key words:
- hepatitis B /
- T-lymphocyte, regulatory /
- nucleoside analogues /
- antiviral therapy
-
[1] TREHANPATI N, HISSAR S, SHRIVASTAV S, et al.Immunological mechanisms of hepatitis B virus persistence in newborns[J].Indian J Med Res, 2013, 138(5):700. [2] EL-BADAWY O, SAYED D, BADARY MS, et al.Relations of regulatory T cells with hepatitis markers in chronic hepatitis B virus infection[J].Human Immunol, 2012, 73(4):335. doi: 10.1016/j.humimm.2012.01.014 [3] SCHMITT EG, WILLIAMS CB.Generation and function of induced regulatory T cells[J].Front Immunol, 2013, 4:152. [4] ZHANG Z, ZHANG JY, WANG LF, et al.Immunopathogenesis and prognostic immune markers of chronic hepatitis B virus infection[J].J Gastroenterol Hepatol, 2012, 27(2):223. doi: 10.1111/jgh.2012.27.issue-2 [5] SAKAGUCHI S, YAMAGUCHI T, NOMURA T, et al.Regulatory T cells and immune tolerance[J].Cell, 2008, 133(5):775. doi: 10.1016/j.cell.2008.05.009 [6] 陈慧娟, 赵守松, 蒋玖.乙型肝炎病毒感染者外周血CD4+CD25+CD127Low/-调节性T淋巴细胞与肝脏病理的关系[J].中华传染病杂志, 2013, 31(10):603. doi: 10.3760/cma.j.issn.1000-6680.2013.10.006 [7] 王宇, 贾继东.慢性乙型肝炎治疗中的几个问题[J].中国实用内科杂志, 2011, 31(7):483. [8] YAN ZH, ZHOU JJ, ZHANG MJ, et al.Telbivudine decreases proportion of peripheral blood CD4+CD25+CD127low T cells in parallel with inhibiting hepatitis B virus DNA[J].Mol Med Rep, 2014, 9(5):2024. doi: 10.3892/mmr.2014.2042 [9] ZHANG J, SONG C, SHI F.Decreased ratio of Treg cells to Th17 cells correlates with HBV DNA suppression in chronic hepatitis B patients undergoing entecavir treatment[J].PLoS One, 2010, 5(11):e13869. doi: 10.1371/journal.pone.0013869 [10] CHEN Y, LI X, YE B, et al.Effect of telbivudine therapy on the cellular immune response in chronic hepatitis B[J].Antiviral Res, 2011, 91(1):23. doi: 10.1016/j.antiviral.2011.04.008 [11] 李成伟, 那妍, 陈佳佳, 等.替比夫定治疗e抗原阳性慢性乙型肝炎患者Treg/Th17比率变化及与抗原血清学转换的关系研究[J].中国实用内科杂志, 2015, 35(6):525. [12] 郑琦, 朱月永, 陈靖, 等.抗病毒治疗后慢性乙型肝炎患者外周血免疫细胞的改变与HBeAg血清学阴转的关系[J].中华肝脏病杂志, 2012, 20(11):801. doi: 10.3760/cma.j.issn.1007-3418.2012.11.001
计量
- 文章访问数: 3773
- HTML全文浏览量: 1951
- PDF下载量: 0
- 被引次数: 0